OncoSec Medical Inc. , a company developing DNA-based intratumoral cancer immunotherapies, plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with Triple Negative Breast Cancer .
from Content Keyword RSS http://ift.tt/1y31hsc
via IFTTT
from Content Keyword RSS http://ift.tt/1y31hsc
via IFTTT
No comments:
Post a Comment